Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis

Chihiro Hasegawa, Helen Kastrissios, Jonathan Monteleone, Tomoya Ohno, Takeo Umemura, Michiyo Ohyama, Shinichi Nagase, Maria Small, Steve Deacon, Mikio Ogawa, Ichiro Ieiri

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

ONO-5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. The objectives of this modeling study were to (1) develop exposure-response (E-R) models to relate ONO-5334 exposure to bone mineral density (BMD), (2) predict BMD responses to various doses of ONO-5334 for both immediate release tablet (IRT) and sustained release tablet (SRT) formulations where only BMD response after administration of IRT had been studied to date, (3) inform selection of appropriate formulation/dose using simulation for future clinical trials. A population pharmacokinetic (PK) model was developed to simultaneously analyze data for both IRT and SRT. The exposure metrics at steady state were estimated by post hoc Bayesian prediction using the final population PK model. E-R models were developed using dose-ranging data with only IRT from postmenopausal females with osteoporosis. Based on the developed model, lumbar spine and total hip BMD after administration of ONO-5334 SRT as well as IRT were simulated. The simulation results showed that ONO-5334 SRT should provide comparable BMD responses at a lower dose relative to IRT (a finding consistent with the results from a previous population PK-PD modeling study with bone resorption markers).

元の言語英語
ページ(範囲)937-948
ページ数12
ジャーナルJournal of Clinical Pharmacology
54
発行部数8
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Cathepsin K
Bone Density
Tablets
Osteoporosis
Pharmacokinetics
ONO-5334
Pelvic Bones
Population
Bayes Theorem
Bone Resorption
Spine
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

これを引用

Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis. / Hasegawa, Chihiro; Kastrissios, Helen; Monteleone, Jonathan; Ohno, Tomoya; Umemura, Takeo; Ohyama, Michiyo; Nagase, Shinichi; Small, Maria; Deacon, Steve; Ogawa, Mikio; Ieiri, Ichiro.

:: Journal of Clinical Pharmacology, 巻 54, 番号 8, 01.01.2014, p. 937-948.

研究成果: ジャーナルへの寄稿記事

Hasegawa, C, Kastrissios, H, Monteleone, J, Ohno, T, Umemura, T, Ohyama, M, Nagase, S, Small, M, Deacon, S, Ogawa, M & Ieiri, I 2014, 'Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis', Journal of Clinical Pharmacology, 巻. 54, 番号 8, pp. 937-948. https://doi.org/10.1002/jcph.279
Hasegawa, Chihiro ; Kastrissios, Helen ; Monteleone, Jonathan ; Ohno, Tomoya ; Umemura, Takeo ; Ohyama, Michiyo ; Nagase, Shinichi ; Small, Maria ; Deacon, Steve ; Ogawa, Mikio ; Ieiri, Ichiro. / Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis. :: Journal of Clinical Pharmacology. 2014 ; 巻 54, 番号 8. pp. 937-948.
@article{d770b5ff79764779a566115e6584d3e7,
title = "Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis",
abstract = "ONO-5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. The objectives of this modeling study were to (1) develop exposure-response (E-R) models to relate ONO-5334 exposure to bone mineral density (BMD), (2) predict BMD responses to various doses of ONO-5334 for both immediate release tablet (IRT) and sustained release tablet (SRT) formulations where only BMD response after administration of IRT had been studied to date, (3) inform selection of appropriate formulation/dose using simulation for future clinical trials. A population pharmacokinetic (PK) model was developed to simultaneously analyze data for both IRT and SRT. The exposure metrics at steady state were estimated by post hoc Bayesian prediction using the final population PK model. E-R models were developed using dose-ranging data with only IRT from postmenopausal females with osteoporosis. Based on the developed model, lumbar spine and total hip BMD after administration of ONO-5334 SRT as well as IRT were simulated. The simulation results showed that ONO-5334 SRT should provide comparable BMD responses at a lower dose relative to IRT (a finding consistent with the results from a previous population PK-PD modeling study with bone resorption markers).",
author = "Chihiro Hasegawa and Helen Kastrissios and Jonathan Monteleone and Tomoya Ohno and Takeo Umemura and Michiyo Ohyama and Shinichi Nagase and Maria Small and Steve Deacon and Mikio Ogawa and Ichiro Ieiri",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/jcph.279",
language = "English",
volume = "54",
pages = "937--948",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis

AU - Hasegawa, Chihiro

AU - Kastrissios, Helen

AU - Monteleone, Jonathan

AU - Ohno, Tomoya

AU - Umemura, Takeo

AU - Ohyama, Michiyo

AU - Nagase, Shinichi

AU - Small, Maria

AU - Deacon, Steve

AU - Ogawa, Mikio

AU - Ieiri, Ichiro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - ONO-5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. The objectives of this modeling study were to (1) develop exposure-response (E-R) models to relate ONO-5334 exposure to bone mineral density (BMD), (2) predict BMD responses to various doses of ONO-5334 for both immediate release tablet (IRT) and sustained release tablet (SRT) formulations where only BMD response after administration of IRT had been studied to date, (3) inform selection of appropriate formulation/dose using simulation for future clinical trials. A population pharmacokinetic (PK) model was developed to simultaneously analyze data for both IRT and SRT. The exposure metrics at steady state were estimated by post hoc Bayesian prediction using the final population PK model. E-R models were developed using dose-ranging data with only IRT from postmenopausal females with osteoporosis. Based on the developed model, lumbar spine and total hip BMD after administration of ONO-5334 SRT as well as IRT were simulated. The simulation results showed that ONO-5334 SRT should provide comparable BMD responses at a lower dose relative to IRT (a finding consistent with the results from a previous population PK-PD modeling study with bone resorption markers).

AB - ONO-5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. The objectives of this modeling study were to (1) develop exposure-response (E-R) models to relate ONO-5334 exposure to bone mineral density (BMD), (2) predict BMD responses to various doses of ONO-5334 for both immediate release tablet (IRT) and sustained release tablet (SRT) formulations where only BMD response after administration of IRT had been studied to date, (3) inform selection of appropriate formulation/dose using simulation for future clinical trials. A population pharmacokinetic (PK) model was developed to simultaneously analyze data for both IRT and SRT. The exposure metrics at steady state were estimated by post hoc Bayesian prediction using the final population PK model. E-R models were developed using dose-ranging data with only IRT from postmenopausal females with osteoporosis. Based on the developed model, lumbar spine and total hip BMD after administration of ONO-5334 SRT as well as IRT were simulated. The simulation results showed that ONO-5334 SRT should provide comparable BMD responses at a lower dose relative to IRT (a finding consistent with the results from a previous population PK-PD modeling study with bone resorption markers).

UR - http://www.scopus.com/inward/record.url?scp=84903956924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903956924&partnerID=8YFLogxK

U2 - 10.1002/jcph.279

DO - 10.1002/jcph.279

M3 - Article

VL - 54

SP - 937

EP - 948

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 8

ER -